(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 August 2008 (07.08.2008)

PCT

(10) International Publication Number
WO 2008/092466 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 31/12* (2006.01)
A61K 31/195 (2006.01)

(21) International Application Number:
PCT/EG2007/000002

(22) International Filing Date: 31 January 2007 (31.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant and
(72) Inventor: **ABDUL AZIZ, Sherif Salah** [EG/EG]; 151 EL Marg, EL Sharkia, Cairo (EG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

WO 2008/092466 A1

(54) Title: ANTIVIRAL COMBINATION FOR TREATMENT OF HCV & HBV

(57) Abstract: The invention concerns a new antiviral combination against HCV and HBV of synthetic amino acid drug with antifibrinolytic action and two types of antibodies. The mechanism results from the effects of the antibodies which enhance the immune system and neutralize the mechanism of the virus against the human immune system while the amino acid plays the main role by stopping the direct effects of the virus on fibrinogen components.